Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS: In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups. RESULTS: Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change −1.3% from 7.7% at start), whereas 39% (n = 323) did not (−0.6% from 8.3% at start). During run-in, 167 of 988 (17%) withdrew; 46% of these due to gastrointestinal adverse events. At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference −0.52 [95% CI −0.68 to −0.36]; P < 0.0001). Forty-three percent of participants with insulin detemir versus 17% without reached A1C <7%. Mean weight decreased by 3.5 kg during run-in, then by 0.16 kg with insulin detemir or 0.95 kg without insulin detemir. In the randomized phase, no major hypoglycemia occurred and minor hypoglycemia rates were 0.286 and 0.029 events per participant-year with and without insulin detemir (9.2 vs. 1.3%). CONCLUSIONS: Supplementation of metformin with liraglutide and then insulin detemir was well tolerated in the majority of patients, with good glycemic control, sustained weight loss, and very low hypoglycemia rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Use of the amylin analog pramlintide in conjunction with bolus insulin improves both glycemia and weight in persons with T2D.1092,1093”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1092]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“greater glycemic efficacy and weight loss (6), they may be more beneficial than these oral agents after metformin, but less acceptable in some patients because of gastrointestinal side effects and the injection barrier.”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationInternational Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“The higher dose may have favored efficacy outcomes and weight loss but adversely affected tolerability (11,24).”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Research works printed but not linked: 1
- Samarasinghe, 2008, The short term effects of exenatide therapy in insulin treated patients with type 2 diabetes mellitus–a new option to achieve weight loss (Abstract), Diabetologia, 51, S353
Cited by
Items 101–158 of 158
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.025 · Cited by 11
Hirsch, I. B., Buse, J. B., Leahy, J. L., McGill, J. B., Peters, A. L., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12136 · Cited by 11
“8 mg, once daily) added to metformin for 12 weeks, followed by the addition of open-label insulin detemir (or continuation of liraglutide without insulin) in patients failing to achieve an A1C <7% (<53 mmol/mol) [63].”
MethodSelf-citationImpact of Newer Medications for Type 2 Diabetes on Body Weight
Pedersen, S. D. (2013) · Current Obesity Reports · doi:10.1007/s13679-012-0045-4 · Cited by 10
“95 kg of weight loss without insulin detemir; A1C and body weight changes were sustained at 1 year [51, 52].”
BackgroundMethods to enhance delivery of prandial insulin and basal‐prandial insulin
Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12067 · Cited by 8
“[22] recently published their data on the addition of insulin detemir to patients receiving liraglutide and metformin, which may be indicative of future treatment trends where GLP-1 RAs are used earlier in the treatment paradigm [23], what is more germane to the discussion herein, are data on the addition of GLP-1 RAs…”
BackgroundWilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Self-citationA systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
“In some of these, lipase levels varied across trial arms, but these variations were not predictive of GI symptoms or pancreatitis [24,139].”
BackgroundSelf-citationLiraglutide (Saxenda®) as a Treatment for Obesity
Onge, E. S., Miller, S. A., & Motycka, C. A. (2016) · Food and Nutrition Sciences · doi:10.4236/fns.2016.74024 · Cited by 15
“However, combination therapy with long acting insulin has been evaluated in two studies [32] [33].”
ResultDavid, J., & Fonseca, V. A. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107473 · Cited by 8
Treatment evaluation of liraglutide in type 2 diabetes
Kela, R., & Davies, M. J. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.716823 · Cited by 7
Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 7
New avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Lipowsky, C., Sze, L., Krull, I., & Brändle, M. (2015) · Diabetes Therapy · doi:10.1007/s13300-014-0093-8 · Cited by 7
“6% due to side effects was comparable to other reports [18, 19].”
Antidiabetic treatment: Though lovers be lost, love shall not
Παπάνας, Ν., & Maltezos, E. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i9.158 · Cited by 7
Incretin mimetics and insulin — closing the gap to normoglycaemia
Nauck, M. A., & Meier, J. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.180 · Cited by 7
Morales, J., & Merker, L. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0208-2 · Cited by 7
“02% increase in HbA1c with continued liraglutide plusmetformin alone [52].”
BackgroundNew Potentiometric Sensor for Determination of Metformin
Кормош, Ж., Kormosh, N., Golub, S., Pachenko, Y., Yurchenko, O. M., Савчук, Т. І., Korolchuk, S., БОРКОВА, С., & Супрунович, С. В. (2022) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-022-02765-1 · Cited by 6
A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes
Cornell, S. A. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12040 · Cited by 6
“A novel treatment intensification sequence (metformin then liraglutide, followed by titration of detemir) results in good glycaemic control, sustained weight loss and minimal hypoglycaemia.(50) Glargine + exenatide improves glycaemic control without increased hypoglycaemia or weight gain and lowers PPG, fasting plasma…”
BackgroundYe, X., Qi, J., Wu, Q., Yu, D., Li, S., Wu, Y., & Li, D. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.025 · Cited by 6
Nodular panniculitis in a female toy poodle.
Post, K. (1983) · PubMed · Cited by 8
Kiyosue, A., Seino, Y., Nishijima, K., Bosch‐Traberg, H., & Kaku, K. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12759 · Cited by 5
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.023 · Cited by 5
Detemir (Levemir): modern paradigms of insulin therapy
Руяткина, Л. А., & Sorokin, M. (2013) · Problems of Endocrinology · doi:10.14341/probl201359456-64 · Cited by 5
Schernthaner, G., Rosas-Guzmán, J., Dotta, F., Guerci, B., Simó, R., Festa, A., Kiljanski, J. I., Zhou, M., & Gallwitz, B. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12471 · Cited by 5
Sieber, J., Weinheimer, M., Kongable, G., Riddle, S., Chang, Y.-Y., & Flacke, F. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819861586 · Cited by 5
Simpson, R., & King, A. B. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1017562 · Cited by 4
Jimeno, C., Kho, S., Santos, G. K. D. L., Buena-Bobis, N., & Villa, M. L. (2018) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.033.02.02 · Cited by 4
Should we Fear Insulin Therapy in the Treatment of Type 2 Diabetes?
Haslam, D. B. (2014) · The Open Obesity Journal · doi:10.2174/1876823701406010070 · Cited by 4
Buturović, B. A. –., Burnazović-Ristić, L., & Narancic, A. (2014) · Medical Archives · doi:10.5455/medarh.2014.68.313-316 · Cited by 5
“This justifies the importance of the use of GLP1 analogues in combination with long-acting insulin analogue (6,7,8).”
BackgroundNauck, M. A., & Meier, J. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch48 · Cited by 4
Gallwitz, B. (2014) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.02.98 · Cited by 4
Hirsch, I. B., Schneider, D., King, A., Polonsky, W. H., Reid, T., Shubrook, J. H., Verderese, C. A., Wallace, J. I., & Riddle, M. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2763 · Cited by 3
GLP‐1 receptor agonists and insulin: where are we now?
Cowan, J., McKay, G., & Fisher, M. (2012) · Practical Diabetes · doi:10.1002/pdi.1720 · Cited by 3
Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth
Wood, J., & Silverstein, J. H. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328362fdfb · Cited by 3
“There were no major episodes of hypoglycemia in either group [17].”
BackgroundVedtofte, L., Knop, F. K., & Vilsbøll, T. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1029455 · Cited by 3
Schmidt, J. B., Sjödin, A. M., Stevner, L., Ritz, C., Michaelsen, N. B., Thomsen, A. B., Holst, J. J., & Astrup, A. V. (2016) · Physiological Reports · doi:10.14814/phy2.12980 · Cited by 2
Self-citationGlucagon-like peptide-1 agonists for weight loss in people with obesity
Kirk, S., Shamliyan, T., & Middleton, M. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.01.003 · Cited by 2
Noh, J. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.127 · Cited by 2
“0% 정도 더 감소한 효 과를 보였고[19-24], 기저인슐린 단독요법 대비 당화혈색소 가 0.”
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
“Recent evidence indicates that the addition of insulin detemir to a combination of metformin and the GLP-1 RA liraglutide can further reduce A1C levels, and ADA/EASD do recommend such combinations (Figure 1).(6,120) There are several approaches for addition or substitution of insulin for patients with T2DM.”
BackgroundCombination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Insulin Therapy in Type 2 Diabetes
Moghissi, E. S. (2013) · US Endocrinology · doi:10.17925/use.2013.09.01.6 · Cited by 2
Pashkova, E. Y. (2013) · Problems of Endocrinology · doi:10.14341/probl201359450-55 · Cited by 1
Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes
Gallwitz, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.29 · Cited by 1
Scheen, A. J., & Paquot, N. (2014) · JMIG · doi:10.53738/revmed.2014.10.439.1549 · Cited by 1
Zinych, О. В., Kushnariova, N. M., Ковальчук, А., Prybila, O. V., Shyshkan-Shyshova, К. О., Gurina, N. M., & Korpachev, V. V. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.7.79.2016.86417 · Cited by 1
Association of serum amylase and lipase levels in newly diagnosed type 2 diabetes mellitus
Hareesh, R., Harish, K. V., & Savith, A. (2021) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20210101 · Cited by 2
“Similarly previous studys also found that the same results says that synthesis, excretion and degradation of serum amylase and lipase levels altered that given the limited pathological changes in T2DM and also they reported that several possible explanations for increased levels of serum amylase and lipase levels in n…”
ResultManagement of Type 2 diabetes with liraglutide
Bohl, M., Overgaard, A., Pietraszek, A., & Hermansen, K. (2014) · Diabetes Management · doi:10.2217/dmt.13.72 · Cited by 1
Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?
Guerci, B., & Sauvanet, J.-P. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70536-4
The place of IDegLira in the management of patients with Type 2 diabetes
Lansdown, A., Bain, S. C., & Chudleigh, R. A. (2015) · Diabetes Management · doi:10.2217/dmt.15.29
Self-citationTreatment: Concepts and new developments
Bloomgarden, Z. T., & Drexler, A. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12381
“Approaches to minimize weight gain include insulin administration with metformin(9,10) and with glucagon-like peptide-1 receptor agonists (GLP-1RA),(11) although the latter approach is not necessarily associatedwith a lessening of hypoglycaemia.(12)”
BackgroundEvaluation and Treatment of Insulin Resistance and Hyperglycemic States
Hurley, D. L., & Zangeneh, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_13
Montvida, O. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122920
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1076-0738 · Cited by 1
“In der sogenannten LiraglutidDetemir-Studie wurden jedoch Typ-2-Diabetiker mit maximaler Dosierung von Liraglutid, aber einem über 12 Wochen Behandlung nicht optimierbaren HbA1c-Wert ≥ 7% als „Non-Responder“ betrachtet und gezielt einer Kombination mit einem Basalinsulin zugeführt [72].”
BackgroundSelf-citationGallwitz, B. (2013) · Der Diabetologe · doi:10.1007/s11428-012-1018-7
Modulation of fat oxidation: nutritional and pharmacological approach
van Can, J. G. P. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20121031jc
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
METFORMIN-SENSITIVE ION-SELECTIVE ELECTRODE
Кормош, Ж., Savchuk, L., Kormosh, N., ШЕВЧУК, М., Lyushuk, K., Савчук, Т. І., & Korolchuk, S. (2022) · Scientific Bulletin of the Uzhhorod University Series «Chemistry» · doi:10.24144/2414-0260.2022.1.70-77
МЕТФОРМІН-ЧУТЛИВИЙ ПОТЕНЦІОМЕТРИЧНИЙ СЕНСОР
Кормош, Ж., SAVCHUK, L., КОРМОШ, Н., ШЕВЧУК, М., ЛЮШУК, К., Савчук, Т. І., & Korolchuk, S. (2022) · Проблеми хімії та сталого розвитку · doi:10.32782/pcsd-2022-2-5
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Metadata
- Authors
- DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Swansea University (GB)
- Endocrine and Metabolic Associates, Rockville, Maryland
- University Medical Center Freiburg (DE)
- Cincinnati VA Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Medical City Dallas Hospital (US)
- Corresponding author
- Rosenstock, Julio
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-06-12
- Volume
- 35
- Issue
- 7
- Pages
- 1446-1454
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3379583
- OpenAlex
- W2160274347
- Cited by
- 159
- References
- 27
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 9 · 2017: 6 · 2016: 18 · 2015: 25 · 2014: 27 · 2013: 33 · 2012: 13
- FWCI
- 25.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- Funders
- American Diabetes Association
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Intarcia Therapeutics
- MannKind Corporation
- MacroGenics
- Diabetes UK
- Novo Nordisk
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, liraglutide, insulin detemir, weight loss, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, glycemic control
- MeSH terms
- Insulin Detemir, Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Insulin, Long-Acting, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.